Searched for
ACN STOCK
Accenture logs $18 billion Q3 revenue, revenue misses estimatesAccenture's Q3 FY26 results revealed a slowdown in IT demand, with the company missing revenue estimates and lowering its full-year guidanc...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Timeless poetry of the day by Charles Bukowski: 'Some people never go crazy. What truly horrible lives they must lead...'Charles Bukowski’s writing continues to resonate because of how honestly he explored loneliness, emotional exhaustion and the struggles of ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%To get clarity on the markets, there are three questions to which you need answers. First: When will the war end? Second: How long will it ...
- Accenture stock drops despite beating Q4 earnings estimate & strong revenue guidanceAcn stock today latest news: Accenture stock experienced a slight dip despite exceeding expectations in its fourth-quarter 2025 earnings re...
- Prashant Jain picks 1.1% stake in microcap firm in Q4; stock jumps 13%Star investor Prashant Jain picked up a 1.08% stake in Kaya Ltd, acquiring 1.42 lakh shares worth around Rs 3.5 crore in Q4. Kaya shares su...
- Stocks in news: Sula Vineyards, Gujarat Gas, JSW Steel, ABFRL, NHPCSaudi Aramco has fixed September propane contract price at $550/tn as against current price of Rs $470/tn. In India, these prices will be a...
- We continuously evolve and believe that every successful formula has an expiry date, says Mankind Pharma’s Rajeev JunejaMankind Pharma's IPO will open on April 25. Rajeev Juneja, VC & MD, shares the company's journey from starting with an initial capital of R...
- Brokerages up price targets on rising Sun, some point to cloudsMotilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edel...
- Sensex jumps 150 pts, Nifty50 reclaims 10,900; Tata Motors, Bharti Airtel lead gainsThe BSE Sensex climbed over 150 points, before paring some gains.
- Cadila Healthcare rises 2% on USFDA approval to antibiotic drugThis medication is also used for prophylaxis of malaria.
- Sun Pharma surges after USFDA approves drug application for acne treatmentSun Pharma surged over 3% in trade today after the drug major received approval from the US health regulator for its new drug.
- Lupin gets USFDA nod to market generic version of CiproLupin said it has received US health regulator USFDA'S approval to market a generic version of Bayer's Cipro, used to treat infections, in ...
- Ranbaxy sets aside Rs 257.4 crore for impact of USFDA banRanbaxy Laboratories has set aside Rs 257.4 crore towards the financial impact of a US ban on import of products made at its plant at Toans...
- Ranbaxy shares surge nearly 6% as Q4 net loss narrowsShares of Ranbaxy Laboratories today gained nearly 6 per cent after the company's fourth quarter net loss narrowed to Rs 158.94 crore.
- Sun Pharma to buy US-based DUSA Pharmaceuticals for $230 millionUnder the terms of agreement, a 100% subsidiary of Sun Pharma will commence a tender offer for all outstanding common stock of DUSA at a pr...
- Glaxo to buy Stiefel Laboratories for $2.9 billionBritish drug maker GlaxoSmithKline PLC said Monday it will pay $2.9 billion to buy American dermatology business Stiefel Laboratories Inc.
- Satyam scam: Infosys, IBM, Accenture may benefit mostInfosys Technologies is expected to gain the most among the top Indian IT players from Satyam’s loss of credibility. Should govt bail Satya...
- Dr Reddy's in skin-care product distribution pact with US firmDr Reddy's Laboratories on Thursday said it has entered into an agreement with US-based dermatology and aesthetic medicine company Cosmeder...
- Ranbaxy buys rights for 13 dermatology productsRanbaxy Laboratories on Monday said it has acquired the US marketing rights for 13 dermatology products from Bristol-Myers Squibb Company (...
Load More
